Anavex生命科學 AVXL 深 滬
交易中 10-30 11:26:10 美东时间
8.21
+0.190
+2.37%
華盛通- 最 高8.298
- 今 開8.00
- 成交量 22.23万股
- 最 低 7.98
- 昨 收 8.02
- 總市值 7.05亿
- 52周最高 14.4405
- 市盈率 靜 --
- 換手率 0.26%
- 52周最低 7.16
- 委 比 -88.64%
- 總股本 8589.38万
- 歷史最高 31.50
- 量 比 0.71
- 振 幅 3.97%
- 歷史最低 0.60
- 每 手 1
- 風險率 1.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
今天 14:22
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $46 price target.
10-29 20:43
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
Anavex reports sustained cognitive benefits from oral blarcamesine, showing slower Alzheimer's progression and long-term efficacy over 144 weeks.
10-29 19:31
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
Anavex Life Sciences announced positive findings for oral blarcamesine in treating early Alzheimer’s disease, showing a significant cognitive benefit compared to the ADNI control group. At Week 144, the ADAS-Cog13 score difference was −12.78 (P < 0.0001), with 77.4 weeks of disease progression delay. Blarcamesine restores autophagy, addressing early molecular changes, and demonstrated a favorable safety profile.
10-29 11:30
Jones Trading Downgrades Anavex Life Sciences to Hold
Jones Trading analyst Soumit Roy downgrades Anavex Life Sciences (NASDAQ:AVXL) from Buy to Hold.
10-24 20:14
TPG & Corpay Complete Acquisition of AvidXchange
AvidXchange Holdings, Inc., a leading provider of accounts payable automation software, has been acquired by TPG and Corpay for $10.00 per share, valuing the company at approximately $2.2 billion. The transaction, which closed on October 15, 2025, removes AvidXchange from the NASDAQ Global Select Market. Michael Praeger, CEO of AvidXchange, expressed excitement about leveraging the partnership with TPG and Corpay to accelerate innovation and expa...
10-15 13:20
Anavex Highlights Oral Blarcamesine's Patient-Centric Alzheimer's Care At Alzheimer Europe Conference Via Prof. Dr. Timo Grimmer's Phase IIb/III Study Presentation
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia,
10-10 19:31
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’
Anavex Life Sciences Corp. announced that Prof. Dr. Timo Grimmer presented on "Advancing Alzheimer’s Disease Care with Oral Blarcamesine" at the 35th Alzheimer Europe Conference. The presentation highlights the convenience and potential benefits of blarcamesine, Anavex’s lead drug candidate, for both Alzheimer's patients and their families. Blarcamesine has successfully completed multiple clinical trials and is designed to target SIGMAR1 and musc...
10-10 11:30
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
Anavex rises after mid-stage trial data for schizophrenia candidate
Anavex Life Sciences (NASDAQ:AVXL) traded higher in the premarket on Thursday after the New York-based biotech said that a mid-stage trial for its experimental antipsychotic ANAVEX 3-71 reached the pr...
10-02 19:50
